| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 |
| 02 Oct 2026 |
8-K: Other Events
BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, BioAge Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals: |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk... |
| 22 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
As representatives (the “Representatives”) of the several Underwriters |
| 20 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026 |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk |
| 04 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2025, BioAge Labs, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals: |
| 04 Jun 2025 |
8-K: Other Events
On June 4, 2025, the Company announced, in its corporate presentation, updates related to anticipated timing of certain milestones, including the following: |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25 |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity |
| 27 Sep 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SHARE PURCHASE AGREEMENT (this “Agreement”) is entered into as of September 25, 2024 (the “Effective Date”), by and between Sofinnova Venture Partners XI, L.P. (the “Investor”), and BioAge Labs, Inc., a Delaware corporation (the “Co... |
Loading...